Literature DB >> 31962276

hsa_circ_0062389 promotes the progression of non-small cell lung cancer by sponging miR-103a-3p to mediate CCNE1 expression.

Yahui She1, Yuanyuan Han1, Guangting Zhou1, Fangyan Jia1, Tan Yang1, Zuojun Shen2.   

Abstract

Recently, increasing evidence showed that circular RNAs (circRNAs) play critical roles in tumor progression. However, the roles of hsa_circ_0062389 in non-small cell lung cancer (NSCLC) development remain unclear. In the present study, hsa_circ_0062389 expression was significantly increased in NSCLC tissues and cell lines. High hsa_circ_0062389 expression was associated with advanced TNM stage and lymph-node metastasis. Function assays showed that hsa_circ_0062389 suppression reduced NSCLC cells proliferation and arrested cell cycle in G0/G1 phase. In mechanism, hsa_circ_0062389 directly interacted with miR-103a-3p in NSCLC, and CCNE1 acted as a target of miR-103a-3p. Furthermore, rescue assays showed that miR-103a-3p suppression or CCNE1 overexpression abolished the effects of hsa_circ_0062389 suppression on lung cancer cells progression. Therefore, our results showed that the hsa_circ_0062389/miR-103a-3p/CCNE1 axis might contribute to the tumorigenesis of NSCLC, which provided a new strategy for cancer treatment.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CCNE1; Non-small cell lung cancer; hsa_circ_0062389; miR-103a-3p

Year:  2019        PMID: 31962276     DOI: 10.1016/j.cancergen.2019.12.004

Source DB:  PubMed          Journal:  Cancer Genet


  9 in total

1.  Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma.

Authors:  Jintao Gu; Nan Mu; Bo Jia; Qingdong Guo; Luxiang Pan; Maorong Zhu; Wangqian Zhang; Kuo Zhang; Weina Li; Meng Li; Lichun Wei; Xiaochang Xue; Yingqi Zhang; Wei Zhang
Journal:  Neuro Oncol       Date:  2022-07-01       Impact factor: 13.029

2.  Circ_0072088 promotes the development of non-small cell lung cancer via the miR-377-5p/NOVA2 axis.

Authors:  Zhaofeng Tan; Fang Cao; Bin Jia; Lei Xia
Journal:  Thorac Cancer       Date:  2020-06-11       Impact factor: 3.500

Review 3.  Biogenesis, functions, and clinical implications of circular RNAs in non-small cell lung cancer.

Authors:  Ying Liu; Xiang Ao; Wanpeng Yu; Yuan Zhang; Jianxun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2021-11-19       Impact factor: 8.886

4.  Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis.

Authors:  Peng Su; Feng Mao; Jian Zhang; Hui Zhang; MingBo Wang; YanZhao Xu; ZiQiang Tian
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Network Pharmacology and Comparative Transcriptome Reveals Biotargets and Mechanisms of Curcumol Treating Lung Adenocarcinoma Patients With COVID-19.

Authors:  Lu Yang; Hao Xiong; Xin Li; Yu Li; Huanhuan Zhou; Xiao Lin; Ting Fung Chan; Rong Li; Keng Po Lai; Xu Chen
Journal:  Front Nutr       Date:  2022-04-19

Review 6.  Circle the Cardiac Remodeling With circRNAs.

Authors:  Tiqun Yang; Tianxin Long; Tailai Du; Yili Chen; Yugang Dong; Zhan-Peng Huang
Journal:  Front Cardiovasc Med       Date:  2021-06-25

7.  MicroRNA-103a Curtails the Stemness of Non-Small Cell Lung Cancer Cells by Binding OTUB1 via the Hippo Signaling Pathway.

Authors:  Zhenzhen Hu; Dan Xiao; Tingting Qiu; Jun Li; Zhentian Liu
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec

8.  Circular RNA circ_0062389 modulates papillary thyroid carcinoma progression via the miR-1179/high mobility group box 1 axis.

Authors:  Yujuan Wang; Huafeng Zong; Haicheng Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

9.  Sevoflurane Suppresses Colon Cancer Cell Malignancy by Regulating circ-PI4KA.

Authors:  Suqing Sun; Peng Wang; Lijie Ren; Hongli Wang; Yanli Zhan; Shimin Shan
Journal:  Onco Targets Ther       Date:  2021-05-20       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.